The chief executive recently conducted a podcast on the Uptick Network Stock Day, where he spoke about the firm's growing sales and its sales teams.
From having just one salesperson previously, he told presenter Everett Jolly: "We now have six sales people, we have a brand new award-winning instrument that is opening up doors and areas of biopharma companies, that we could never have got into before."
Last month the group revealed its next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME - had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
"This company is at an all time high in its potential and its ability to succeed and bring back a great return on investment for investors, and yet we've been hitting our all-time lows in the past month as a stock price," explained Schumacher.
"Our sales are increasing and our stock price is really not responding."
"We've already broken US$1mln in the first half of the year. In the third quarter, I've already given guidance that investors should expect a record number for our third quarter. Things aren't going down, things are actually moving up.." he added.
Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.
The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.
The group is a pressure expert and UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch)
"The company believes that UST has the potential to play a significant role in a number of commercially important areas, including the formulation of high quality stable nanoemulsions and the preparation of extended shelf-life "clean label" food," it told investors.
Shares in New York added 3.24% on the day to US$4.14 each.